NCT02651259: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02651259 |
|---|---|
| Title | A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 13, 2017 |
| Completion date | April 10, 2019 |
| Required reporting date | April 9, 2020, midnight |
| Actual reporting date | April 3, 2020 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |